natural glp-1 agonists and the kidney: from physiology to pharmacology and outcomes in diabetes GLP-1 receptor agonists and next-generation
Description
A powerhouse of obesity research then and now. September 20, 2024
The ADA notes that medication adjustments should be individualized based on the patient's glycemic control, with appropriate glucose monitoring during any interruption period
doi:10.1136/bmj-2024-080679 Written by Dr
Clin Epidemiol 11:349358
The new biology and pharmacology of glucagon
Clinical trials report gastrointestinal adverse events in 40-50% of tirzepatide users, with nausea alone affecting roughly one in three participants
